Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Thursday, 9 November 2017

Active Biotech AB - Interim report January - September 2017

Active Biotech    

Published: 08:30 CET 09-11-2017 /GlobeNewswire /Source: Active Biotech / : ACTI /ISIN: SE0001137985

Active Biotech AB - Interim report January - September 2017

    

 

Third quarter in brief

  • The company's application related to one of the patent families in the SILC project was granted patent in the US
  • Preclinical data for a SILC substance was published in the scientific journal Cancer Immunology Research
  • The process to divest the company's research facility at Ideon in Lund has been initiated, for further comments related to the company's liquidity situation see the section "Outlook, including significant risks and uncertainties"

 

Events after the end of the period

  • In October, Active Biotech's partner Teva Pharmaceutical Industries Ltd presented new data concerning laquinimod for the treatment of multiple sclerosis at the ECTRIMS-ACTRIMS congress
  • The Board of directors has decided to initiate negotiations with the trade unions related to the winding up of the companies animal test facility

 

Financial summary

SEK M

July-Sept.

Jan.-Sept.

Full-year

 

2017

2016

2017

2016

2016

 

 

 

 

 

 

Net sales

5.1

4.1

14.8

12.0

19.0

Operating loss

-6.5

-11.1

-44.2

-41.6

-55.1

Loss for the period

-8.4

-12.4

-48.6

-44.8

-59.6

Loss per share, before and after dilution (SEK)

-0.09

-0.14

-0.50

-0.50

-0.65

Cash and cash equivalents (at the end of the period)

 

 

35.6

39.9

77.7

 

 

For further information, please contact:

  Helén Tuvesson, CEO

  Tel: +46 (0)46-19 21 56

 

  Hans Kolam, CFO

  Tel: +46 (0)46 19 20 44

 

Active Biotech AB

(Corp. Reg. No. 556223-9227)

Box 724, SE-220 07 Lund

Tel: +46 (0)46-19 20 00

 

The report is also available at www.activebiotech.com.



Active Biotech AB - Interim report January - September 2017



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: Active Biotech, Scheelevägen 22
Box 724, LUND 220 07,
If you would like to unsubscribe and stop receiving these e-mails click here.